Company profile: Cytovale
1.1 - Company Overview
Company description
- Provider of early detection diagnostic technologies for immune-mediated diseases, including the IntelliSep Test for rapid sepsis identification with results in under 10 minutes to aid emergency department triage, powered by microfluidics, precision imaging, and machine learning to analyze complex biological data and perform detailed cellular analysis.
Products and services
- IntelliSep Test: Clinical-grade diagnostic that detects sepsis early, delivering results in under 10 minutes to aid patient triage decisions in emergency departments
- Machine Learning: Scalable models applied to analyze complex biological data, enhancing the accuracy and speed of CytoVale's diagnostic tests used for early immune-mediated disease identification
- Microfluidics: Custom-engineered micro-scale flow technology that manipulates and analyzes small fluid volumes, underpinning CytoVale's diagnostic products for early detection of immune-mediated diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cytovale
Binx Health
HQ: United States
Website
- Description: Provider of point-of-care and at-home diagnostic solutions, including binx io for chlamydia and gonorrhea testing with results in about thirty minutes; at-home STI sample collection kits available via digital health platforms; and at-home COVID-19 nasal swab sample collection kits for individual and bulk orders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Binx Health company profile →
Trius Therapeutics
HQ: United States
Website
- Description: Provider of discovery, development and commercialization of innovative antibiotics for life-threatening infections. Completed two Phase 3 clinical trials for Tedizolid Phosphate (TR-701), formerly torezolid phosphate, in ABSSSI, with IV and orally administered formulations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trius Therapeutics company profile →
AN2 Therapeutics
HQ: United States
Website
- Description: Provider of boron chemistry–based drug discovery and clinical development for infectious diseases, including epetraborole, an oral therapy in development for chronic non-tuberculous mycobacterial lung disease targeting Mycobacterium avium complex, and conducting clinical trials to obtain regulatory approval for new medications for infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AN2 Therapeutics company profile →
Kramer Labs
HQ: United States
Website
- Description: Provider of branded over-the-counter medicines in the foot care and cough-cold segments of the consumer healthcare market, offering products such as Nizoral A-D Anti-Dandruff Shampoo, Opti-Nail Fungal Nail Repair Pen, Kaopectate Diarrhea & Upset Stomach Reliever, Colace Stool Softener, Senokot laxatives, and NATURELO premium supplements.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kramer Labs company profile →
Affinium Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceutical research and development focused on novel anti-infective medicines, advancing FASII antibacterial programs as a new antibiotic franchise with potential for multiple products targeting the FASII pathway, supported by a broad base of long-term intellectual property.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Affinium Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cytovale
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cytovale
2.2 - Growth funds investing in similar companies to Cytovale
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cytovale
4.2 - Public trading comparable groups for Cytovale
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →